- Decrease font
- Increase font
- Send to a friend
Click here to bookmark this page
Customize your Bookmarks:
- Type the name of the page the way you would like it to appear in "My Bookmarks";
- Click in the "Add as My Bookmarks" button.
To choose your favorite sessions, please click here.
Grupo Fleury growth goes through the following fronts to be explored in the healthcare value chain:
- Organic expansion in PSCs business. Guidance of 73 to 90 new PSCs between 2017 and 2021 (54 PSCs already delivered)
- Continue to be the leader of genomics segment in Brazil and increase revenue participation from 1% (2017) to 5% (2022)
- New offerings beyond diagnostics: primary care, healthcare coordination, drug infusion, orthopedic procedures and others
- Company’s digital transformation: medical knowledge, clients relationship, back office processes and others
- Strong pillar on innovation: R&D, startups and technical partnerships
- M&A Opportunities to become the market consolidator in the diagnostic segment 19
To know more about the Grupo Fleury strategy, access the Institutional and the Fleury Investor‘s Day presentations.